Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6 Pt 2
|
pubmed:dateCreated |
1991-1-31
|
pubmed:abstractText |
This study examines the receptor mechanisms by which dopamine (DA) inhibits Na(+)-K(+)-adenosinetriphosphatase (ATPase) activity in single permeabilized proximal tubule (PCT). Na(+)-K(+)-ATPase activity was inhibited in the presence of both DA1- and DA2-specific agonists but not by either agonist alone. The inhibition induced by DA (10(-6) M) was attenuated in the presence of either of the two DA2-specific antagonists S-sulpiride and YM 09151 at 10(-5) M and in the presence of the DA1 antagonist SCH 23390 (10(-5) M). PCT adenosine 3',5'-cyclic monophosphate (cAMP) levels were significantly increased in the presence of DA and DA1 agonist, but DA2 agonist had no effect on cell cAMP levels. Na(+)-K(+)-ATPase activity was significantly inhibited in PCT incubated with DA2 agonist (10(-5) M) and dibutyryl (DB)-cAMP (10(-6) M) but not with DA2 agonist (10(-5) M) only. PCT Na(+)-K(+)-ATPase activity was also significantly inhibited in the presence of both DA2 agonist (10(-5) M) and forskolin (10(-6) M). Neither DBcAMP (10(-6) M) nor forskolin (10(-6) M) alone inhibited Na(+)-K(+)-ATPase activity. In tubules incubated with DA (10(-8) to 10(-9) M), the presence of DBcAMP (10(-6) M) enhanced the sensitivity by which DA inhibited Na(+)-K(+)-ATPase activity. We conclude that PCT Na(+)-K(+)-ATPase activity is inhibited by a synergistic action of the DA1 and DA2 receptors, with the DA1 receptor acting to increase cell cAMP levels.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bucladesine,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic AMP,
http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Forskolin,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Dopamine,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Dopamine D1,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Dopamine D2,
http://linkedlifedata.com/resource/pubmed/chemical/Sodium-Potassium-Exchanging ATPase
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0002-9513
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
259
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
F924-8
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1979719-Animals,
pubmed-meshheading:1979719-Bucladesine,
pubmed-meshheading:1979719-Cyclic AMP,
pubmed-meshheading:1979719-Dopamine,
pubmed-meshheading:1979719-Dopamine Agents,
pubmed-meshheading:1979719-Dopamine Antagonists,
pubmed-meshheading:1979719-Drug Synergism,
pubmed-meshheading:1979719-Enzyme Activation,
pubmed-meshheading:1979719-Forskolin,
pubmed-meshheading:1979719-Kidney Tubules, Proximal,
pubmed-meshheading:1979719-Male,
pubmed-meshheading:1979719-Rats,
pubmed-meshheading:1979719-Receptors, Dopamine,
pubmed-meshheading:1979719-Receptors, Dopamine D1,
pubmed-meshheading:1979719-Receptors, Dopamine D2,
pubmed-meshheading:1979719-Sodium-Potassium-Exchanging ATPase
|
pubmed:year |
1990
|
pubmed:articleTitle |
Inhibition of proximal tubule Na(+)-K(+)-ATPase activity requires simultaneous activation of DA1 and DA2 receptors.
|
pubmed:affiliation |
Department of Pediatrics, St. Göran's Children's Hospital, Karolinska Institute, Stockholm, Sweden.
|
pubmed:publicationType |
Journal Article
|